| Dr Megan Lynn Cope, OD | |
|
940 Belmont St, Brockton, MA 02301-5596 | |
| (774) 826-1106 | |
| Not Available |
| Full Name | Dr Megan Lynn Cope |
|---|---|
| Gender | Female |
| Speciality | Optometrist |
| Location | 940 Belmont St, Brockton, Massachusetts |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1194935668 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | 4607 (Massachusetts) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Megan Lynn Cope, OD Po Box 990519, Boston, MA 02199-0519 Ph: (617) 877-1599 | Dr Megan Lynn Cope, OD 940 Belmont St, Brockton, MA 02301-5596 Ph: (774) 826-1106 |
News Archive
Heart attack patients treated with primary percutaneous intervention (PCI) at hospitals after hours and on weekends wait longer to receive clot busters and other treatments and have a higher risk of death than those treated during regular hospital hours
KRG Capital Partners, a Denver-based buyout firm, completed its sale of ATI Holdings ("ATI") to GTCR Golder Rauner LLC ("GTCR"). The transaction closed on March 12, 2010. The all cash sale represents KRG's first full exit in its $715 million Fund III. ATI is a provider of outpatient physical therapy services with an offering that includes physical rehabilitation, hand therapy, aquatic therapy, work conditioning/work hardening, sports medicine and functional capacity assessments.
For the first time, researchers are using proteomics to examine proteins and peptides in saliva in order to accurately detect exposure to Zika virus.
Boehringer Ingelheim will present a pooled analysis of new data from the Phase 3 UniTinA-asthma® program at the European Respiratory Society (ERS) Annual Congress 2013 in Barcelona. The data from the individual MezzoTinA-asthma® Phase 3 studies (NCT01340209 and NCT00565266), from which the pooled data are derived, show the addition of tiotropium delivered via the Respimat® inhaler to medium-dose maintenance inhaled corticosteroid (ICS) therapy (defined as 400-800 µg budesonide/day or equivalent) improved lung function and provided sustained bronchodilation over 24 hours in patients with moderate asthma and airflow limitation. Tiotropium is being investigated to determine the medicine's efficacy in treating asthma patients and is not currently approved for this indication.
› Verified 1 days ago
Lynn Brandes, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 21 Torrey St, Brockton, MA 02301 Phone: 508-587-8344 | |
Edna Chiu, Optometrist Medicare: Accepting Medicare Assignments Practice Location: 21 Torrey Street, Brockton, MA 02301 Phone: 508-717-0425 | |
Dr. Barry M Fisch, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 940 Belmont St, Brockton, MA 02301 Phone: 774-826-1106 | |
Mass Optometric Associates, P.c. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 726 1/2 Belmont St, Taymor Shoe Plaza, Brockton, MA 02301 Phone: 508-587-9700 Fax: 508-587-0646 | |
Dr. Richard M Lubas, O.D. Optometrist Medicare: May Accept Medicare Assignments Practice Location: 700 Oak St, Brockton, MA 02301 Phone: 508-584-8886 Fax: 508-584-8500 | |
Dr. Bryanna Morgan Caron, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 940 Belmont St, Brockton, MA 02301 Phone: 508-583-4500 |